TScan Therapeutics Has Appointed Gavin MacBeath As The Interim Principal Financial Officer, Effective July 21, 2023, Replacing Brian Silver, Who Had Previously Announced His Resignation As CFO; MacBeath Has Been Serving As CEO Since May 24, 2023 - 8K
Portfolio Pulse from Benzinga Newsdesk
TScan Therapeutics has announced the appointment of Gavin MacBeath as the Interim Principal Financial Officer, effective from July 21, 2023. He replaces Brian Silver, who had previously announced his resignation as CFO. MacBeath has been serving as CEO since May 24, 2023.
July 25, 2023 | 11:20 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
TScan Therapeutics has appointed Gavin MacBeath as the Interim CFO, replacing Brian Silver. MacBeath has been serving as CEO since May 2023.
The appointment of a new CFO is a significant event for a company. However, as MacBeath is already serving as CEO, the transition might be smoother. The impact on the stock price is uncertain in the short term, hence the neutral score.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100